A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation studyJesse J. Swen, Roelof Bosch, Erika Cecchin et al.|The Lancet|2023Cited by 508
Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapyAnna Reustle, Elke Schaeffeler|Genome Medicine|2020Cited by 102
Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinomaFlorian Büttner, Elke Schaeffeler|BMC Medicine|2018Cited by 30
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapyFlorian Büttner, Elke Schaeffeler|Genome Medicine|2022Cited by 29